Clinical Trial Search

Primary: Percentage Change From Baseline in the LDL-C/HDL-C Ratio — -50.9; -53.0; -37.6; -42.4 Percentage Change — p=<0.001

Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change

Primary: Reduction of LDL Cholesterol Levels — -39.45; -29.13 percent change of LDL — p=0.0013

Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L

Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL

Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006

Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001

Primary: Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy — -44.8…

Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants

Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change

Primary: LDL Goal Attainment — 6; 6; 9 participants

Primary: Change From Baseline in Direct LDL-C at Week 8 — -2.0; -1.5; -4.2; 0.2 Percent change — p=0.06

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment — -32.2; -20.8 percentage change — p=0.005

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.8; -50.8 percent change — p=<0.001

Primary: Percent Change From Baseline at Week 24 in Fasting TG — -1.7; -51.5; -57.7; -64.1 percentage change — p=<0.0001

Primary: Basal HDL-cholesterol Level — 39.5 mg/dL

Primary: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C — -45.58; 3.03 percent change from baseline — p=<.0001

Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L

Primary: Total Cholesterol Before and After Simvastatin/Ezetimibe Administration — 255; 253; 180; 215 mg/dl — p=<0.05

Primary: Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) — -17.9; -25.0; -26.6; -2.1 Percent Change — p=<0.0001

Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 8; 10; 8; 11 Participants

Primary: Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12 — -34.8; -22.7 percent

Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001

Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid

Primary: Mean Percent Change in Triglycerides From Baseline to Final Visit — -45.6; -42.1; -29.6; -16.5 percent change — p=<0.001

Primary: The Apolipoprotein A-I Fractional Catabolic Rate (FCR) — 0.294; 0.294; 0.295 pools/day — p=>0.5

Primary: Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level — -31.3; -32.8 Percent change